Liver transplantation for hepatocellular carcinoma: our experience from 1986

Pérez-Saborido, B.; Segurola, Carmelo Loinaz; Calvo, Amelia Serraller; Díaz, Juan Carlos Meneu; Usera, M. Abradelo de; Pulido, Jorge Calvo; Romero, Carlos Jiménez; Sanz, R Gómez; García, Ignacio; González, Esther

doi:10.1016/s0041-1345(03)00581-5

Cited by 19 publications

(9 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The second cause of decease was viral relapse, due especially to the C-virus. These data are similar to those published by other authors (19).…”

Section: Discussionsupporting

confidence: 93%

“…It depends on the bibliography and it oscillates between 15 and 50% (19)(20)(21)(22). In the sample of our hospital it has been 32,1%.…”

Section: Discussionmentioning

confidence: 81%

“…These variables have been already validated and cited as risk factors by other authors (13,19,(23)(24)(25). In the multivariate analysis, only the size of the nodules and the vascular invasion have been proved to be independent risk factors, as some other authors have already said (13,19,23,26). The microscopic vascular invasion is a high risk factor of tumor relapse.…”

Section: Discussionmentioning

confidence: 81%

See 2 more Smart Citations

Survival of patients receiving a liver transplant for hepatocellular carcinoma, and risk of tumor recurrence

Luque

Vallejos

Álvarez

et al. 2006

Rev. esp. enferm. dig.

View full text Add to dashboard Cite

Objective: the goal of this research has been to evaluate the survival, in long and short term, of the patient receiving liver transplant for hepatocellular carcinoma (HCC), the risk of posttransplant tumor relapse and factors related to this complication.Design: retrospective study of a consecutive series of patients having had liver transplant for HCC.Patients and methodology: transplant patients for HCC from 1989 to November 2003. Patients were selected due to general limitations of nodule size and quantity, which were subsequently published as Milan criteria. Also, criteria agreed in the Conference of Barcelona were followed in the pre-transplant diagnosis.Results: the survival of this 81 patients group was of the 80, 61 and 52% for 1, 5 and 10 years respectively. In the 32% of the cases the HCC was an incidental finding in the explant. In the 12.3%, the tumor relapse was verified. The multivariate research identified the size of the nodule (OR = 1,7944) (IC 95% = 1,1332-2,8413) and the vascular invasion (OR = 6,6346) (IC 95% = 1,4624-30,1003) as risk factors of relapse.Conclusions: the liver transplant in selected patients with HCC has good results in medium and long term. The risk of post-transplant tumor relapse becomes notably reduced and is associated with the size of the nodule and the microscopic vascular invasion.

show abstract

“…The second cause of decease was viral relapse, due especially to the C-virus. These data are similar to those published by other authors (19).…”

Section: Discussionsupporting

confidence: 93%

“…It depends on the bibliography and it oscillates between 15 and 50% (19)(20)(21)(22). In the sample of our hospital it has been 32,1%.…”

Section: Discussionmentioning

confidence: 81%

Section: Discussionmentioning

confidence: 81%

See 1 more Smart Citation

Survival of patients receiving a liver transplant for hepatocellular carcinoma, and risk of tumor recurrence

Luque

Vallejos

Álvarez

et al. 2006

Rev. esp. enferm. dig.

View full text Add to dashboard Cite

show abstract

“…Factors affecting tumor recurrence of HCC after liver transplantation have been previously reported with preoperative AFP levels [30,31], tumor size [32,33], histologic grade [33,34], and vascular invasion [33,35]. Our experimental results suggest cellular differentiation (p = 0.001), tumor stage (p = 0.032), and tumor size (p = 0.021) in HCC were significantly associated with HCC-specific disease-free survival after liver transplantation.…”

Section: Discussionmentioning

confidence: 99%

Yes-Associated Protein Expression is a Predictive Marker for Recurrence of Hepatocellular Carcinoma after Liver Transplantation

Wang

et al. 2014

Dig Surg

View full text Add to dashboard Cite

Purpose: To explore the expression of Yes-associated protein (YAP) in hepatocellular carcinoma (HCC) patients, and assess its prognostic value to recurrence of HCC after liver transplantation (LT). Methods: Collected data of 105 consecutive patients undergoing LT for HCC were analyzed retrospectively. The immunohistochemistry was used to detect the expression of YAP, Mst1, Lats1/2, pYAP, pLats1/2 and pMst1/2 in tumor tissues. Contingency table and χ²-test were used to investigate the correlation between expression of YAP, Mst1, Lats1/2 and clinical characteristics. Univariate survival analysis and Multivariate Cox regression analysis were also performed to analyze the correlation of clinical and pathological factors with tumor recurrence after LT. The Kaplan-Meier method and log-rank test were used to analyze HCC-specific disease-free survival (DFS) rate. Results: Forty patients fulfilled Milan criteria with 1-, 2-, 3- and 5-years DFS of 86.7, 84.6, 84, 84%, respectively. The positive rates of YAP, Lats1/2, Mst1 in HCC were 51.4, 45.7, 64.8%, respectively. YAP expression in HCC tumors was significantly associated with tumor size (p = 0.041), venous infiltration (p = 0.002), AJCC tumor stage (p = 0.027). Lats1/2 expression was significantly associated with tumor size (p = 0.001) and AJCC tumor stage (p = 0.019). Mst1 expression was also significantly associated with tumor size (p = 0.042). HCC-specific DFS was significantly longer for patients with YAP negative expression compared with patients with YAP positive expression (1-, 2-, 3- and 5-years DFS of 71.7, 65.3, 65.3, 65.3 vs. 42.5, 36.6, 32.5, 30.4%, respectively, log-rank = 12.89, p < 0.001). Multivariate Cox regression analysis indicated that YAP expression (HR = 2.011, p = 0.020) in HCC was an independent prognostic factor for HCC-specific DFS after liver transplantation. Conclusions: YAP is an independent prognostic marker for tumor recurrence for HCC patients after liver transplantation.

show abstract

“…It is clear that tumor recurrence and/or metastasis must be controlled in order to improve the eYcacy of OLT in HCC treatment. Studies have examined the relationship between immunosuppressive agents and recurrence Vivarelli et al 2002), explored the connection between vascular inWltration and recurrence (Lee et al 2005;Perez Saborido et al 2003), investigated the relevance of AFP level to recurrence (Shao et al 2006) and assessed the eVects of peri-surgical adjuvant therapies on recurrence (Ravaioli et al 2004). Once multiple recurrences and/or metastases appear, treatment strategies are limited; the most widely used method is post-operative chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

Feasibility of 125I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma

Li¹,

Zhang

Zhang³

et al. 2010

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

Liver transplantation for hepatocellular carcinoma: our experience from 1986

Cited by 19 publications

References 7 publications

Survival of patients receiving a liver transplant for hepatocellular carcinoma, and risk of tumor recurrence

Survival of patients receiving a liver transplant for hepatocellular carcinoma, and risk of tumor recurrence

Yes-Associated Protein Expression is a Predictive Marker for Recurrence of Hepatocellular Carcinoma after Liver Transplantation

Feasibility of 125I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma

Contact Info

Product

Resources

About